

COMPANY OVERVIEW

Propanc is currently focused on developing new cancer treatments for patients suffering from pancreatic, ovarian and colorectal cancers. We have developed a formulation of anti-cancer compounds which exert a number of effects designed to control or prevent tumors from recurring and spreading throughout the body. Our products involve or employ proenzymes, which are inactive precursors of enzymes.

RECENT NEWS

[Propanc Biopharma Receives Expression of Interest to Evaluate Proenzyme Therapy in Pancreatic and Ovarian Cancer Patients](#)

Jan 18 2021, 8:30 AM EST

[Propanc Biopharma Analyzes Pancreatic Proenzymes Vs T-Cell Therapy Targeting Solid Tumors Such as Pancreatic, Ovarian & Colorectal Cancers](#)

Jan 11 2021, 8:30 AM EST

[Propanc Biopharma Advances POP1 Joint Research and Drug Discovery Program for Projected US\\$111.2B Global Metastatic Cancer Market](#)

Dec 30 2020, 8:30 AM EST

STOCK OVERVIEW

Symbol	PPCB
Exchange	OTCQB
Market Cap	152.75k
Last Price	\$0.221
52-Week Range	\$0.22 - \$264.80

01/22/2021 03:59 PM EST

INVESTOR RELATIONS

Propanc Biopharma, Inc.
T: +61-03-9882-6723
irteam@propanc.com

MANAGEMENT TEAM

James Nathanielsz
CEO, Executive Chairman and CFO

Dr. Julian Kenyon, M.D.
Chief Scientific Officer

Professor Klaus Kutz, M.D.
Chief Medical Officer

PROPANC BIOPHARMA, INC.

302/6 Butler Street
Camberwell, VIC 3124
AU

DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.